Modern Diagnostic IPO Description – Modern Diagnostic & Research is a leading provider of diagnostic and related healthcare testing services in India, operating through a network of 21 centers, including 18 laboratories and 3 diagnostic centers across 8 states. Specializing in both pathology and radiology, the company offers an extensive portfolio of services such as MRI, […]
Modern Diagnostic IPO GMP, Review, Price, Allotment Read More »
Bengaluru-based Tonbo Imaging India, a pioneering defence electronics manufacturer, has filed its DRHP with the Securities and Exchange Board of India (SEBI). The move signals the company’s intention to list on Indian bourses and represents another milestone in the country’s growing ecosystem of indigenous defence technology enterprises. Tonbo Imaging IPO Structure & Key Details Tonbo
India’s Biggest Defence Optics OEM Tonbo Imaging Files For IPO Read More »
Bengaluru-based Tonbo Imaging India, a pioneering defence electronics manufacturer, has filed its DRHP with the Securities and Exchange Board of India (SEBI). The move signals the company’s intention to list on Indian bourses and represents another milestone in the country’s growing ecosystem of indigenous defence technology enterprises. Tonbo Imaging IPO Structure & Key Details Tonbo
India’s Biggest Defence Optics OEM Tonbo Imaging Files For IPO Read More »
As the calendar year 2025 draws to a close, the Indian primary market continues to witness a flurry of regulatory activity. In a significant move to cap off a blockbuster year for listings, the Securities and Exchange Board of India (SEBI) has issued final “observations” to three distinct companies, effectively granting them the green light
As the calendar year 2025 draws to a close, the Indian primary market continues to witness a flurry of regulatory activity. In a significant move to cap off a blockbuster year for listings, the Securities and Exchange Board of India (SEBI) has issued final “observations” to three distinct companies, effectively granting them the green light
ICICI Securities has initiated coverage on The Leela Palaces Hotels & Resorts (LEELA) with a ‘BUY’ rating and a target price of INR 600, implying a ~46% upside from the current market price of INR 411. The brokerage values Leela’s core hotels business at 22x Dec’27E EV/EBITDA, adding a 1x P/B multiple for its high-value
ICICI Securities Initiates Coverage On Leela Hotels With ‘BUY’, Sets ₹600 Target Read More »
ICICI Securities has initiated coverage on The Leela Palaces Hotels & Resorts (LEELA) with a ‘BUY’ rating and a target price of INR 600, implying a ~46% upside from the current market price of INR 411. The brokerage values Leela’s core hotels business at 22x Dec’27E EV/EBITDA, adding a 1x P/B multiple for its high-value
ICICI Securities Initiates Coverage On Leela Hotels With ‘BUY’, Sets ₹600 Target Read More »
India’s infrastructure expansion is no longer a policy aspiration—it is an economic reality reshaping the nation’s industrial and logistics backbone. With a projected infrastructure investment of nearly INR 143 lakh crore (~USD 1.7 trillion) between FY24 and FY30, and annual railway capital expenditure exceeding INR 2.6 lakh crore in FY25, the government has made rail
P/E 14–15x For A Rail Automation Niche, Value, Fair, Or Risky? Read More »
India’s infrastructure expansion is no longer a policy aspiration—it is an economic reality reshaping the nation’s industrial and logistics backbone. With a projected infrastructure investment of nearly INR 143 lakh crore (~USD 1.7 trillion) between FY24 and FY30, and annual railway capital expenditure exceeding INR 2.6 lakh crore in FY25, the government has made rail
P/E 14–15x For A Rail Automation Niche, Value, Fair, Or Risky? Read More »
As India’s industrial landscape accelerates under the twin engines of Make in India and massive infrastructure investments, the demand for high-performance lubricants and specialty oils is surging. In this evolving ecosystem, Sundrex Oil Company — a Kolkata-based manufacturer is entering the capital markets with an IPO that offers investors a window into one of the
57% Revenue CAGR And Expanding Margins—Should You Apply? Read More »